{
    "elements": [
        {
            "type": "image",
            "sequence_num": 1,
            "data": {
                "url": "MSEPO-21089 Vinca Alkaloids Policy.001.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 2,
            "data": {
                "num_rows": 16,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Title:"
                    },
                    {
                        "text": "VINCA ALKALOIDS POLICY"
                    },
                    {
                        "text": "Document Reference/Register no:"
                    },
                    {
                        "text": "MSEPO-21089"
                    },
                    {
                        "text": "Version Number:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Document type: (Policy/ Guideline/ SOP/CCP)"
                    },
                    {
                        "text": "Policy"
                    },
                    {
                        "text": "To be followed by: (Target Staff)"
                    },
                    {
                        "text": "all clinical, nursing and pharmacy staff, involved with vinca alkaloid medicines"
                    },
                    {
                        "text": "Ratification Issue Date: (Date document is uploaded onto the intranet)"
                    },
                    {
                        "text": "25 May 2021"
                    },
                    {
                        "text": "Review Date:"
                    },
                    {
                        "text": "24 May 2024"
                    },
                    {
                        "text": "Key word(s) to search for document on intranet:"
                    },
                    {
                        "text": "Vinca, vinka, alkaloids, vincristine, vinblastine, vindesine, vinorelbine"
                    },
                    {
                        "text": "Developed in response to: (National Guidance/Recommendations (i.e. NICE; RCOG)"
                    },
                    {
                        "text": "NPSA/2008/RRR004"
                    },
                    {
                        "text": "Contributes to HSC Act 2008 (Regulated Activities) Regulations 2014(Part 3); and CQC Regulations 2009 (Part 4) CQC Fundamental Standards of Quality and Safety:"
                    },
                    {
                        "text": "12"
                    },
                    {
                        "text": "Issuing Division/Directorate:"
                    },
                    {
                        "text": "Division 9, Pharmacy"
                    },
                    {
                        "text": "Author/Contact: (Asset Administrator)"
                    },
                    {
                        "text": "Simon Worrall"
                    },
                    {
                        "text": "Deputy Chief Pharmacist"
                    },
                    {
                        "text": "Hospital Sites: (tick appropriate box(s) to indicate status of policy review i.e. joint/ independent)"
                    },
                    {
                        "text": "\u2612 MSE NHS Foundation Trust \u2610 Basildon Hospital \u2610 Broomfield Hospital \u2610 Southend Hospital \u2610 Other (please state)"
                    },
                    {
                        "text": "Approval Group / Committee(s):"
                    },
                    {
                        "text": "MSE Medicines Assurance Group Chair action E.Allen in Lieu"
                    },
                    {
                        "text": "21 May 2021"
                    },
                    {
                        "text": "Professionally Approved by: (Asset Owner)"
                    },
                    {
                        "text": "Evelyn Allen"
                    },
                    {
                        "text": "Chief Pharmacist"
                    },
                    {
                        "text": "21 May 2021"
                    },
                    {
                        "text": "Consultation:"
                    },
                    {
                        "text": "(Refer to page 2)"
                    },
                    {
                        "text": "Ratification Group(s):"
                    },
                    {
                        "text": "Joint Document Management Group"
                    },
                    {
                        "text": "25 May 2021"
                    },
                    {
                        "text": "Executive and Clinical Directors (Communication of minutes from Joint Document Management Group)"
                    },
                    {
                        "text": "June 21"
                    },
                    {
                        "text": "Distribution Method:"
                    },
                    {
                        "text": "\u2612 Trust Intranet"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "image",
            "sequence_num": 3,
            "data": {
                "url": "MSEPO-21089 Vinca Alkaloids Policy.002.png"
            }
        },
        {
            "type": "table",
            "sequence_num": 4,
            "data": {
                "num_rows": 4,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Consulted With: (Must include Specialist Pharmacists if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "Jennie Joyce"
                    },
                    {
                        "text": "Lead Oncology & Haematology Pharmacist - Southend"
                    },
                    {
                        "text": "30 April 2021"
                    },
                    {
                        "text": "Alex Wan"
                    },
                    {
                        "text": "Lead Oncology & Haematology Pharmacist - Basildon"
                    },
                    {
                        "text": "20 May 2021"
                    },
                    {
                        "text": "Hannah Overland"
                    },
                    {
                        "text": "Deputy Director of Nursing \u2013 Cancer, Palliative Care & End of Life"
                    },
                    {
                        "text": "21 May 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 5,
            "data": {
                "num_rows": 2,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Post/ Approval Committee/ Group: (Must include Medication Assurance Group if the document has any reference to medication)"
                    },
                    {
                        "text": "Date:"
                    },
                    {
                        "text": "MSE Medicines Assurance Group Chair action E.Allen in Lieu"
                    },
                    {
                        "text": "21 May 2021"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 6,
            "data": {
                "num_rows": 2,
                "num_cols": 1,
                "table_items": [
                    {
                        "text": "Related Trust Policies (to be read in conjunction with)"
                    },
                    {
                        "text": "Site Guidelines for the administration of cytotoxic drugs (or equivalent) Administration of Medicines Policy (or equivalent) Prescribing of Medicines Policy (or equivalent) Safe Handling of Medicines Policy (or equivalent) Intrathecal Chemotherapy Policy (or equivalent)"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 7,
            "data": {
                "num_rows": 5,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Document Review History:"
                    },
                    {
                        "text": "Version No:"
                    },
                    {
                        "text": "Authored/Reviewer:"
                    },
                    {
                        "text": "Summary of amendments/ Record documents superseded by:"
                    },
                    {
                        "text": "Issue Date:"
                    },
                    {
                        "text": "1.0"
                    },
                    {
                        "text": "Simon Worrall"
                    },
                    {
                        "text": "25 May 2021"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Contents"
            },
            "type": "ListItem",
            "sequence_num": 8
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.0,
                "text": "Introduction ................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 9
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.0,
                "text": "Scope ........................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 10
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 3.0,
                "text": "Definitions ..................................................................................................................... 4"
            },
            "type": "ListItem",
            "sequence_num": 11
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 4.0,
                "text": "Role & Responsibilities within the Trust ........................................................................ 4"
            },
            "type": "ListItem",
            "sequence_num": 12
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.0,
                "text": "Prescriptions for Vinca Alkaloids .................................................................................. 7"
            },
            "type": "ListItem",
            "sequence_num": 13
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.0,
                "text": "Labelling of Vinca Alkaloids .......................................................................................... 7"
            },
            "type": "ListItem",
            "sequence_num": 14
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 7.0,
                "text": "Dilution of Vinca Alkaloids ............................................................................................ 7"
            },
            "type": "ListItem",
            "sequence_num": 15
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.0,
                "text": "Training ......................................................................................................................... 7"
            },
            "type": "ListItem",
            "sequence_num": 16
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "Monitoring and Audit ..................................................................................................... 7  Approval and Implementation ....................................................................................... 8  Equality Impact Assessment ......................................................................................... 8  References ................................................................................................................... 8 Appendix 1: Preliminary Equality Analysis ........................................................................... 9"
            },
            "type": "ListItem",
            "sequence_num": 17
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 1.0,
                "text": "Introduction"
            },
            "type": "ListItem",
            "sequence_num": 18
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.1,
                "text": "Vinca Alkaloids including, but not exclusively, Vincristine, Vinblastine, Vindesine and Vinorelbine, are anticancer drugs which, if given intrathecally (into the spine), will result in death or severe paralysis."
            },
            "type": "ListItem",
            "sequence_num": 19
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.2,
                "text": "This policy applies to the labelling and dilution of Vinca Alkaloids (including vincristine, vinblastine, vindesine and vinorelbine). If other intravenous Vinca Alkaloids become available, they will be deemed to be covered by the policy."
            },
            "type": "ListItem",
            "sequence_num": 20
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.3,
                "text": "The National Patient Safety Agency Rapid Response Report 2008 RRR004 made recommendations to reduce the incidence of death caused by the mal- administration of Vinca Alkaloids."
            },
            "type": "ListItem",
            "sequence_num": 21
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.4,
                "text": "This policy outlines the recommendations and provides guidance for the safe supply and administration of Vinca Alkaloids in respect of cancer services."
            },
            "type": "ListItem",
            "sequence_num": 22
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 1.5,
                "text": "It applies, primarily to the treatment of adults but includes provision for the treatment of children. The policy should be followed alongside Trust guidelines for the Administration of Cytotoxic Drugs (or equivalent)."
            },
            "type": "ListItem",
            "sequence_num": 23
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 2.0,
                "text": "Scope"
            },
            "type": "ListItem",
            "sequence_num": 24
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 2.1,
                "text": "The purpose of this document is to:"
            },
            "type": "ListItem",
            "sequence_num": 25
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The purpose of this document is to ensure the safe supply, labelling and dilution of Vinca Alkaloids in the Trust."
            },
            "type": "ListItem",
            "sequence_num": 26
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 3.0,
                "text": "Definitions"
            },
            "type": "ListItem",
            "sequence_num": 27
        },
        {
            "type": "table",
            "sequence_num": 28,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "TERM"
                    },
                    {
                        "text": "DEFINITION"
                    },
                    {
                        "text": "Guidance in HSC 2008/001"
                    },
                    {
                        "text": "National guidance provided in Health Service Circular HSC 2008/001 updated national guidance on the safe administration of Intrathecal chemotherapy (August 2008)"
                    },
                    {
                        "text": "Intrathecal"
                    },
                    {
                        "text": "Administration into the spine."
                    },
                    {
                        "text": "NPSA"
                    },
                    {
                        "text": "National Patient Safety Agency"
                    },
                    {
                        "text": "POSCU"
                    },
                    {
                        "text": "Paediatric Oncology Shared Care Unit"
                    },
                    {
                        "text": "MSE or \u2018the Trust'"
                    },
                    {
                        "text": "Mid & South Essex NHS Foundation Trust"
                    },
                    {
                        "text": "Vinca Alkaloid"
                    },
                    {
                        "text": "The following drugs are included in this definition: vincristine, vinblastine, vindesine and vinorelbine."
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.0,
                "text": "Role & Responsibilities within the Trust"
            },
            "type": "ListItem",
            "sequence_num": 29
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "MSE Patient Safety & Quality Group"
            },
            "type": "ListItem",
            "sequence_num": 30
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Receiving exception reports and taking action in response to issues raised from Medicines Assurance Group and/or department of pharmacy."
            },
            "type": "ListItem",
            "sequence_num": 31
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.2,
                "text": "MSE Medicines Assurance Group"
            },
            "type": "ListItem",
            "sequence_num": 32
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring the effective implementation, use and timely review of this policy;"
            },
            "type": "ListItem",
            "sequence_num": 33
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that monitoring arrangements are appropriately performed by the Site Medicines Optimisation and Safety Groups (MOSG);"
            },
            "type": "ListItem",
            "sequence_num": 34
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Where necessary, escalating concerns to the Chief Nursing Officer, site Director of Nursing, Deputy Director of Nursing for Cancer or Chief Medical Officer, site Medical Director, Medical Director for Cancer as appropriate;"
            },
            "type": "ListItem",
            "sequence_num": 35
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Exception reporting to the MSE Patient Safety & Quality Group on developments,"
            },
            "type": "ListItem",
            "sequence_num": 36
        },
        {
            "data": {
                "is_heading": 0,
                "text": "concerns and progress concerning vinca alkaloid use."
            },
            "type": "ListItem",
            "sequence_num": 37
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.3,
                "text": "Site Medicines Optimisation and Safety Group (MOSG)"
            },
            "type": "ListItem",
            "sequence_num": 38
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Monitoring this policy through incident reports;"
            },
            "type": "ListItem",
            "sequence_num": 39
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Escalating issues to divisional governance groups and MAG as appropriate."
            },
            "type": "ListItem",
            "sequence_num": 40
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.4,
                "text": "MSE SACT Quality Group"
            },
            "type": "ListItem",
            "sequence_num": 41
        },
        {
            "data": {
                "is_heading": 0,
                "text": "On-going review and implementation of processes outlined within this document;"
            },
            "type": "ListItem",
            "sequence_num": 42
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that follow-up and investigation of vinca alkaloid incidents is completed in accordance with Trust policies for incident management (MSEPO-19014 & 19015, and medication errors MSEPO-20206;"
            },
            "type": "ListItem",
            "sequence_num": 43
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Facilitating feedback with any actions taken and recommendations for changes in practice;"
            },
            "type": "ListItem",
            "sequence_num": 44
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Reviewing this policy annually to ensure it remains up to date and relevant."
            },
            "type": "ListItem",
            "sequence_num": 45
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.5,
                "text": "MSE Pharmacy Governance Group & Oncology Division Governance Group"
            },
            "type": "ListItem",
            "sequence_num": 46
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Taking action with respect to divisional service delivery."
            },
            "type": "ListItem",
            "sequence_num": 47
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.6,
                "text": "Chief Executive"
            },
            "type": "ListItem",
            "sequence_num": 48
        },
        {
            "data": {
                "is_heading": 0,
                "text": "As the Trust's accountable officer has overall responsibility for ensuring the Trust has robust, complete and up to date documents in place to govern and guide activities so that legal, and national requirements are met."
            },
            "type": "ListItem",
            "sequence_num": 49
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Has the overall responsibility for compliance with guidance in HSC 2008/001."
            },
            "type": "ListItem",
            "sequence_num": 50
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.7,
                "text": "Chief Medical Officer"
            },
            "type": "ListItem",
            "sequence_num": 51
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that there is policy compliance and liaising with the Site Medical Directors that the service is operating effectively;"
            },
            "type": "ListItem",
            "sequence_num": 52
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring sufficient resources are in place to implement this policy"
            },
            "type": "ListItem",
            "sequence_num": 53
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring any escalated vinca alkaloid issues involving professions they oversee are appropriately managed corporately."
            },
            "type": "ListItem",
            "sequence_num": 54
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.8,
                "text": "Site Medical Directors"
            },
            "type": "ListItem",
            "sequence_num": 55
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that there is policy compliance on site by all professions they oversee and that the service is operating effectively;"
            },
            "type": "ListItem",
            "sequence_num": 56
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring any escalated vinca alkaloid issues involving professions they oversee are appropriately managed corporately."
            },
            "type": "ListItem",
            "sequence_num": 57
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.9,
                "text": "Cancer Division Medical Director"
            },
            "type": "ListItem",
            "sequence_num": 58
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring prescribers are implementing and monitoring vinca alkaloid management in their areas;"
            },
            "type": "ListItem",
            "sequence_num": 59
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring areas under their responsibility are appropriately monitored and supported following audit to ensure sustained improvement is achieved;"
            },
            "type": "ListItem",
            "sequence_num": 60
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.1,
                "text": "Chief Nursing Officer"
            },
            "type": "ListItem",
            "sequence_num": 61
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that there is policy compliance and liaising with the Deputy / Chief Pharmacist that the service is operating effectively;"
            },
            "type": "ListItem",
            "sequence_num": 62
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring sufficient resources are in place to implement this policy;"
            },
            "type": "ListItem",
            "sequence_num": 63
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring any escalated vinca alkaloid issues involving professions they oversee are appropriately managed corporately."
            },
            "type": "ListItem",
            "sequence_num": 64
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that safe systems and practices are implemented and maintained within wards, departments and/or teams."
            },
            "type": "ListItem",
            "sequence_num": 65
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring there are systems in place to provide relevant education and training for"
            },
            "type": "ListItem",
            "sequence_num": 66
        },
        {
            "data": {
                "is_heading": 0,
                "text": "nursing staff."
            },
            "type": "ListItem",
            "sequence_num": 67
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.11,
                "text": "Site Director of Nursing / Deputy Director of Nursing for Cancer"
            },
            "type": "ListItem",
            "sequence_num": 68
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that there is policy compliance on site by all professions they oversee and that the service is operating effectively;"
            },
            "type": "ListItem",
            "sequence_num": 69
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring any escalated vinca alkaloid issues involving professions they oversee are appropriately managed corporately;"
            },
            "type": "ListItem",
            "sequence_num": 70
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring sufficient resources are in place to implement this policy;"
            },
            "type": "ListItem",
            "sequence_num": 71
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.12,
                "text": "Chief Pharmacist"
            },
            "type": "ListItem",
            "sequence_num": 72
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Is accountable to the chief executive for ensuring compliance with this policy and that relevant pharmacy staff are aware of its contents."
            },
            "type": "ListItem",
            "sequence_num": 73
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Setting the overall framework and policy standards for vinca alkaloids across the organisation, in line with regulatory and best practice guidance;"
            },
            "type": "ListItem",
            "sequence_num": 74
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring a monitoring process exists and functions for policy standard."
            },
            "type": "ListItem",
            "sequence_num": 75
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Chief Pharmacist delegates this responsibility to the Deputy Chief Pharmacist and site clinical lead pharmacists for delivery."
            },
            "type": "ListItem",
            "sequence_num": 76
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.13,
                "text": "Site Lead Pharmacist for Oncology and Haematology"
            },
            "type": "ListItem",
            "sequence_num": 77
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that prescriptions and dose requests comply with Guidance in HSC 2008/001."
            },
            "type": "ListItem",
            "sequence_num": 78
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.14,
                "text": "MSE Head of Pharmacy Technical Services"
            },
            "type": "ListItem",
            "sequence_num": 79
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that vinca alkaloids are labelled and diluted in accordance with this policy during the dose manufacturing process(s)."
            },
            "type": "ListItem",
            "sequence_num": 80
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.15,
                "text": "All prescribers involved in the prescribing of Vinca Alkaloids"
            },
            "type": "ListItem",
            "sequence_num": 81
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Ensuring that they always comply with the requirements of the policy and ensure all prescriptions / written orders are written in accordance with the law."
            },
            "type": "ListItem",
            "sequence_num": 82
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 4.16,
                "text": "All pharmacy technical services staff"
            },
            "type": "ListItem",
            "sequence_num": 83
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Preparing vinca alkaloids in accordance with this policy and the pharmacy departmental standard operating procedures."
            },
            "type": "ListItem",
            "sequence_num": 84
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 5.0,
                "text": "Prescriptions for Vinca Alkaloids"
            },
            "type": "ListItem",
            "sequence_num": 85
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 5.1,
                "text": "Prescriptions for Vinca Alkaloids must be checked by suitably trained pharmacist(s) in accordance with existing pharmacy procedures to ensure the route is clearly identified as intravenous and the appropriate volume and administration time is specified."
            },
            "type": "ListItem",
            "sequence_num": 86
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.0,
                "text": "Labelling of Vinca Alkaloids"
            },
            "type": "ListItem",
            "sequence_num": 87
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 6.1,
                "text": "Vinca Alkaloids will be labelled with the patient name, hospital identifier, name of product, route of administration and a warning as follows: \u201cFor intravenous use only"
            },
            "type": "ListItem",
            "sequence_num": 88
        },
        {
            "data": {
                "is_heading": 0,
                "text": "\u2013 fatal if administered by other routes.\u201d"
            },
            "type": "ListItem",
            "sequence_num": 89
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 6.2,
                "text": "Negative labelling e.g. \u201cNot for \u2026\u2026use\u201d MUST NEVER be used."
            },
            "type": "ListItem",
            "sequence_num": 90
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.0,
                "text": "Dilution of Vinca Alkaloids"
            },
            "type": "ListItem",
            "sequence_num": 91
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.1,
                "text": "Adult patients"
            },
            "type": "ListItem",
            "sequence_num": 92
        },
        {
            "data": {
                "is_heading": 0,
                "text": "For adult patients, the dose of Vinca Alkaloid will be supplied in a ready to administer 50ml minibag of sodium chloride 0.9%."
            },
            "type": "ListItem",
            "sequence_num": 93
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.2,
                "text": "Adolescent patients"
            },
            "type": "ListItem",
            "sequence_num": 94
        },
        {
            "data": {
                "is_heading": 0,
                "text": "The Trust does not currently have an adolescent unit. If adolescent patients are treated on the adult unit then doses of vinca alkaloids will be provided as for adults i.e. in a ready to administer 50ml minibag of sodium chloride 0.9%."
            },
            "type": "ListItem",
            "sequence_num": 95
        },
        {
            "data": {
                "is_heading": 0,
                "text": "If adolescent patients are treated on the paediatric unit then doses of vinca alkaloids will be provided in a pre-filled syringe diluted with 20ml Sodium Chloride 0.9%."
            },
            "type": "ListItem",
            "sequence_num": 96
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 7.3,
                "text": "Paediatric patients"
            },
            "type": "ListItem",
            "sequence_num": 97
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Currently limited to POSCU service providing Vincristine only."
            },
            "type": "ListItem",
            "sequence_num": 98
        },
        {
            "data": {
                "is_heading": 1,
                "text": "For paediatric patients, the dose of Vinca Alkaloid will always be supplied in a pre-filled syringe diluted with 20ml with Sodium Chloride 0.9%."
            },
            "type": "ListItem",
            "sequence_num": 99
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 8.0,
                "text": "Training"
            },
            "type": "ListItem",
            "sequence_num": 100
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 8.1,
                "text": "Staff being trained in the prescribing, dispensing, administration and checking of intravenous chemotherapy will be made aware of this policy and the need for compliance with it."
            },
            "type": "ListItem",
            "sequence_num": 101
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Monitoring and Audit"
            },
            "type": "ListItem",
            "sequence_num": 102
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 9.1,
                "text": "Outlined below is the Trust's process of monitoring compliance with, and the effectiveness of the document's main points."
            },
            "type": "ListItem",
            "sequence_num": 103
        },
        {
            "type": "table",
            "sequence_num": 104,
            "data": {
                "num_rows": 2,
                "num_cols": 6,
                "table_items": [
                    {
                        "text": "Aspect of compliance or effectiveness being monitored"
                    },
                    {
                        "text": "Monitoring Method"
                    },
                    {
                        "text": "Individual department responsible for the monitoring"
                    },
                    {
                        "text": "Frequency of the monitoring activity"
                    },
                    {
                        "text": "Group / Committee / forum which will receive the findings/monitoring report"
                    },
                    {
                        "text": "Committee / individual responsible for ensuring the actions are completed"
                    },
                    {
                        "text": "Incident management"
                    },
                    {
                        "text": "Incident reports"
                    },
                    {
                        "text": "Oncology and Pharmacy"
                    },
                    {
                        "text": "Monthly"
                    },
                    {
                        "text": "SACT Quality Group Site Medicines Optimisation and Safety Group"
                    },
                    {
                        "text": "Designated ITC Lead. Medicines Assurance Group"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 10.0,
                "text": "Approval and Implementation"
            },
            "type": "ListItem",
            "sequence_num": 105
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.1,
                "text": "All policies, procedures and guidelines will be approved by Medicines Assurance Group, which is the specialist group with the authority to approve local medication documents. These will then be forwarded to the Document control team for submission and ratification by the Joint Document Management Group."
            },
            "type": "ListItem",
            "sequence_num": 106
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 10.2,
                "text": "It is the author's responsibility to inform all prescribers, nursing and pharmacy of the approved policy documents when they are uploaded to the Trust's Intranets."
            },
            "type": "ListItem",
            "sequence_num": 107
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Equality Impact Assessment"
            },
            "type": "ListItem",
            "sequence_num": 108
        },
        {
            "data": {
                "is_heading": 0,
                "prefix": 11.1,
                "text": "The Trust is committed to the provision of a service that is fair, accessible and meets the needs of all individuals."
            },
            "type": "ListItem",
            "sequence_num": 109
        },
        {
            "data": {
                "is_heading": 0,
                "text": "(Refer to appendix 1)"
            },
            "type": "ListItem",
            "sequence_num": 110
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 12.0,
                "text": "References"
            },
            "type": "ListItem",
            "sequence_num": 111
        },
        {
            "data": {
                "is_heading": 0,
                "text": "This document needs to be read in conjunction with:"
            },
            "type": "ListItem",
            "sequence_num": 112
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Department of Health. 11th August 2008. Updated National Guidance on the safe administration of Intrathecal Chemotherapy, HSC 2008/001."
            },
            "type": "ListItem",
            "sequence_num": 113
        },
        {
            "data": {
                "is_heading": 0,
                "text": "National Patients Safety Agency. 2008. Rapid Response Report: Using Vinca Alkaloid Minibags (Adult/Adolescent Units), NPSA/2008/RRR004."
            },
            "type": "ListItem",
            "sequence_num": 114
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Toft, B. 2012. Independent review of the circumstances surrounding a serious untoward incident that occurred in the aseptic manufacturing unit, Royal Surrey County Hospital on Monday, 18 June 2012. accessed via http://www.chfg.org/wp- content/uploads/2013/01/Report-to-medical-Director-RSCH_ProfBToft.pdf"
            },
            "type": "ListItem",
            "sequence_num": 115
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Vinca Alkaloids Policy / MSEPO-21089 / 1.0"
            },
            "type": "ListItem",
            "sequence_num": 116
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 11.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 117
        },
        {
            "data": {
                "is_heading": 0,
                "text": "Vinca Alkaloids Policy / MSEPO-21089 / 1.0"
            },
            "type": "ListItem",
            "sequence_num": 118
        },
        {
            "data": {
                "is_heading": 1,
                "text": "Appendix 1: Preliminary Equality Analysis"
            },
            "type": "ListItem",
            "sequence_num": 119
        },
        {
            "data": {
                "is_heading": 1,
                "text": "This assessment relates to Vinca Alkaloids Policy: (Please tick all that apply)"
            },
            "type": "ListItem",
            "sequence_num": 120
        },
        {
            "type": "table",
            "sequence_num": 121,
            "data": {
                "num_rows": 3,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "\u2610 A change in a service to patients"
                    },
                    {
                        "text": "\u2610 A change to an existing document"
                    },
                    {
                        "text": "\u2610 A change to the way staff work"
                    },
                    {
                        "text": "\u2612 A new document"
                    },
                    {
                        "text": "\u2610 Something else (please give details)"
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    },
                    {
                        "text": ""
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 122,
            "data": {
                "num_rows": 7,
                "num_cols": 2,
                "table_items": [
                    {
                        "text": "Questions"
                    },
                    {
                        "text": "Answers"
                    },
                    {
                        "text": "1."
                    },
                    {
                        "text": "What are you proposing to change?"
                    },
                    {
                        "text": "A Harmonisation for Trust-wide use"
                    },
                    {
                        "text": "2."
                    },
                    {
                        "text": "Why are you making this change? (What will the change achieve?)"
                    },
                    {
                        "text": "Harmonised documentation"
                    },
                    {
                        "text": "3."
                    },
                    {
                        "text": "Who benefits from this change and how?"
                    },
                    {
                        "text": "Staff and Patients have consistent processes applied for high risk medicine"
                    },
                    {
                        "text": "4."
                    },
                    {
                        "text": "Is anyone likely to suffer any negative impact as a result of this change? If no, please record reasons here and sign and date this assessment. If yes, please complete a full EIA."
                    },
                    {
                        "text": "No \u2013 in line with national best practice and mandatory compliance"
                    },
                    {
                        "text": "5."
                    },
                    {
                        "text": "a) Will you be undertaking any consultation as part of this change?"
                    },
                    {
                        "text": "Yes"
                    },
                    {
                        "text": "b) If so, with whom?"
                    },
                    {
                        "text": "Refer to pages 1 & 2"
                    }
                ]
            }
        },
        {
            "type": "table",
            "sequence_num": 123,
            "data": {
                "num_rows": 2,
                "num_cols": 3,
                "table_items": [
                    {
                        "text": "Preliminary analysis completed by:"
                    },
                    {
                        "text": "Name"
                    },
                    {
                        "text": "Simon Worrall"
                    },
                    {
                        "text": "Job Title"
                    },
                    {
                        "text": "Deputy Chief Pharmacist"
                    },
                    {
                        "text": "19 May 2021"
                    }
                ]
            }
        },
        {
            "data": {
                "is_heading": 1,
                "prefix": 9.0,
                "text": "Page  of"
            },
            "type": "ListItem",
            "sequence_num": 124
        }
    ]
}